As one of the largest import and export agents and distributors, kantile's distribution business in China has been the envy of the outside world. The $25.4 billion market and the eighth position of domestic pharmaceutical business are enough to shake up the industry.
On July 24th, reporters from kantile China confirmed that the company had indeed been "exploring the possibility of other strategies". And industry experts said, to be involved in the first round of bidding for the characters (sinopharm), prescription medicine (Shanghai) and the CRC (China resources pharmaceutical business), and number of prescription and CRC 'willingness to bid for the strongest, so which Kant joy eventually sold directly decide who will be the second Chinese medicine business.
Kantian confirms that he intends to do so
After a rapid expansion in China and one of the top drug distributors in China, Kantian was reborn.
Industry from Kant's latest music about China market and its related business distribution changed hands, Kant's music, head of the China related media response said yesterday, in order to achieve Kant music of China in terms of product and service distribution business development potential, the company does, indeed, is exploring other possibility strategy, to support the development of the next stage.
According to the director, according to Kant the in the process of seeking partners, will keep an open mind, "consider strategic partners include industry enterprises, and financial investors such as possible".
As for the outside hearsay state-controlled, prescription and CRC hope flange, Kant's music has admitted that information is so much to say at the moment, other related news, need to be further disclosed.
In addition, kantile China said on July 24 that its other operations and teams in China, including Cordis, will continue to serve the Chinese market as part of kantia. In addition, kantile will continue to invest additional resources in the Asia Pacific region after completing its acquisition of medtronic. In April, Mr Kantile announced a $6.1bn purchase of MDT's medical supplies business, or patient recovery.
The big three bid quietly?
Shanghai pharmaceuticals declined to comment on the bid. China resources medical insider said it was not aware of the situation, but did not directly deny the rumors. In an interview with reporters, gan rongfu, a senior consultant at sinopharm, said the three companies had a common goal to participate in mergers and acquisitions, in order to scale and intensive development.
"If the state-controlled, to more than $200 of revenue is not enough to affect the industry landscape, at present its holdings revenue has nearly 300 billion yuan, is 500 billion yuan. But if gave prescription, the situation would be different." This is the analysis of gan rongfu.
In its view, the Kantian distribution business in China, the biggest impact is the industry second and third.
According to the ministry of commerce issued the medicine circulation industry in 2016 to run statistical analysis report, in 2016 China national pharmaceutical group corporation (sinopharm) parent company, China resources pharmaceutical business and Shanghai pharma ranked top champions league third place, the three main business revenue of about 298.8 billion yuan, 114.6 billion yuan and 113.8 billion yuan respectively.
"If CRC flange, that for medicine, will be a hit. Kant's headquarters in Shanghai with prescription, Kant's music has a lot of foreign agent varieties, these are prescription value. In contrast, China resources pharmaceutical business development focus seems not sole agent medicines." Gan rong fu further analysis.
It is understood that Kantian's business in China is so attractive to the three major pharmaceutical distribution giants in China, and one of the important reasons is that it has the "paved road" in front of the Swiss group.
In 2011, Kant's music through acquisitions Swiss zuellig yongyu pharmaceutical corp., a strong "into China" won the yongyu pharmaceutical 9 large logistics center in mainland China, 330 cities sales channels, and by more than 6700 distributors, 4.9 hospitals, 4.9 retail pharmacies and 1250 sales union composed of the centers for disease control. At the time, yongyu medicine had business with more than 500 Chinese and foreign pharmaceutical companies. Since then, in 2013, kantile has further laid out China's high value drug retail channels through the acquisition of guangzhou baijixinte pharmaceuticals. |
